|
|
|
Volumn 6, Issue 6, 2008, Pages 421-422
|
|
Second-line therapy for ovarian cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
CANFOSFAMIDE;
CARBOPLATIN;
DOXORUBICIN;
GEMCITABINE;
PACLITAXEL;
PLATINUM COMPLEX;
TAXANE DERIVATIVE;
TOPOTECAN;
ARTICLE;
CANCER RECURRENCE;
CANCER RELAPSE;
CANCER RESISTANCE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
COMORBIDITY;
DISEASE FREE SURVIVAL;
DRUG CHOICE;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
EVIDENCE BASED MEDICINE;
HUMAN;
MONOTHERAPY;
NEUROPATHY;
OVARY CANCER;
OVERALL SURVIVAL;
QUALITY OF LIFE;
RETREATMENT;
SURVIVAL TIME;
SYMPTOM;
TREATMENT OUTCOME;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CLINICAL TRIALS AS TOPIC;
FEMALE;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
OVARIAN NEOPLASMS;
TUBULIN MODULATORS;
|
|
EID: 52949107155
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (4)
|
